DOCSLIB.ORG

No Model Dose/Route of Administration Key Findings Ref. Healthy Rodents

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
No Model Dose/Route of Administration Key Findings Ref. Healthy Rodents No Model Dose/route of administration Key findings Ref. Healthy rodents submitted to painful experience 1 Male Wistar Rats intra‐vl‐PAG microinjection of vehicle; CBD (1.5; 3; 6 CBD and CBC: ↓ ongoing acvity of ON and OFF neurons (Maione submitted to tail flick nmol) alone or CBD (3 nmol) in combination with the (dose‐dependently); ↑ annocicepve responses in the tail et al. test and selective antagonists of TRPV1 (I‐RTX, 1 nmol), CB1 flick‐test (effects antagonized by selective antagonists of CB1 2011) measurement of the (AM251, 0.5 nmol), adenosine A1 (DPCPX, 0.05 nmol), adenosine A1 and TRPA1, but not of TRPV1 receptors); ↑ electrical activity of TRPA1 (AP18, 6 nmol), 5‐HT1A (WAY100635, 0.34 nmol); endocannabinoid levels in the ventrolateral periaqueductal anaesthetizes rat’s CBC (3; 6 nmol) alone or CBC (6 nmol) in combination grey ON and OFF neurons with I‐RTX (1 nmol), AM251 (0.5 nmol), DPCPX (0.05 OMDM‐2 and mustard oil: similar effects of the rostral nmol) or AP18 (6 nmol); OMDM‐2 (selective inhibitor of ventromedial endocannabinoid cellular reuptake, 1.5; 3 nmol) or medulla mustard oil (TRPA1 channels agonist, 3; 6 nmol) 2 Male and female Experiment 1: CBD (0, 10, 30 mg/kg) 15 min before Δ9‐ Experiment 1: (Britch et Sprague‐Dawley rats THC (0, 1.8, 3.2, 5.6, 10 mg/kg); test 15–360 min post‐Δ9‐ al. 2017) CBD alone: no antinociceptive effects; ↑ locomotor acvity tested on tail THC injection withdrawal, paw CBD+Δ9‐THC: ↑ THC‐induced paw pressure but not tail Experiment 2: CBD (30 mg/kg) 13 h or 15 min before Δ9‐ pressure and withdrawal antinociception; ↑ Δ9‐THC‐induced THC (1.8 mg/kg); test 30–480 min post‐Δ9‐THC injection locomotor activity hypolocomotion at lower Δ9‐THC doses tests Experiment 3: CBD (30 mg/kg) 13 h or 15 min before Δ9‐ No sex differences in CBD‐Δ9‐THC interactions THC (1.8 mg/kg); serum samples taken 30–360 min post‐ Δ9‐THC injection Experiments 2 and 3: CBD: no enhancement of Δ9‐THC’s effects; ↓ THC metabolism (effect greater in females than males) 3 Male and female Twice‐daily treatment with vehicle, CBD (10 mg/kg), Δ9‐ Δ9‐THC day 1: more potent in females than in males (both (Greene Sprague‐Dawley rats THC (3.6 mg/kg females; 9.3 mg/kg males) or CBD+Δ9‐ nociceptive tests) et al. submitted to tail THC for 4 days 2018) Δ9‐THC days 1‐6: ↓ of potency on the tail withdrawal test withdrawal and paw (more in females than males) pressure tests CBD+Δ9‐THC days 1‐6: greater rightward/downward shifts of the Δ9‐THC dose‐effect curve than Δ9‐THC alone Day 6 blood samples: higher serum Δ9‐THC levels in CBD+Δ9‐ THC‐treated females than in vehicle + Δ9‐THC‐treated females; Δ9‐THC’s active metabolite 11‐OH‐ Δ9‐THC and its inactive metabolite Δ9‐THC‐COOH: lower in CBD + Δ9‐THC‐ treated rats than in vehicle+ Δ9‐THC‐treated rats (both sexes); CBD: ↑ serum levels of the active metabolite cannabinol (both sexes) 4 Male Wistar Rats Naloxone (3.0 mg/kg), diazepam (1.5 mg/kg) or CBD (0.75 Naloxone and CBD: ↓ nocicepve threshold; ↓ tail‐flick (Gonçalve submitted to mg/kg,1.5 mg/kg, 3.0 mg/kg, 4.5 mg/kg, 6.0 mg/kg and latencies s et al. transcutaneous 12.0 mg/kg) i.p. 10 min after the acute administration,10 2014) Diazepam: no alterations in the nociceptive threshold electrical nerve Hz or 150 Hz TENS was performed for 30 min stimulation (TENS) and the tail‐flick test Neuropathic pain 5 Sciatic nerve injury Gelatin oral self‐administration paradigm ‐ mice Δ9‐THC gelatin: ↓ allodynia; ↓ hyperalgesia; ↓ ultrasonic (Abraham mouse model consumed Δ9‐THC‐, CBD‐, or morphine‐containing vocalizations et al. gelatins ad libitum for 3 weeks 2020) CBD gelatin: ↓ allodynia; ↓ ultrasonic vocalizaons Morphine gelatin: ↓ allodynia (tolerance aer 1 week); ↓ ultrasonic vocalizations 6 Ligation of L5 spinal CBD (3, 10, 50 ug i.t.) CBD and its modified derivatives: ↓ chronic neuropathic pain (Xiong et nerve neuropathic (positively correlated with cannabinoid potentiation of the α3 al. 2012) Dihydroxyl‐CBD, DH‐CBD (10, 30, 50 mg/kg i.p.) pain model in rats GlyRs, but not with their binding affinity for CB1 and CB2 Didesoxy‐CBD, DD‐CBD (0.1, 1, 10, 15 mg/kg i.p.) receptors); ↑ glycine currents in dorsal horn neurons in rat spinal cord slices Antagonist tested: strychnine 1 µM (GlyR antagonist) 7 Foramen Rotundum orally ‐ 5 uL of whole plant extracted hemp oil combined CBD: ↓ mechanical allodynia within 1 h with a peak reversal (Vigil et Inflammatory with a peanut butter vehicle (0.138 mg/kg) effect at 4 h; remained significant throughout the 6 h al. 2020) Constriction Trigeminal Infraorbital Nerve injury mouse model 8 Sciatic nerve chronic Oral administration of CBD (2.5–20 mg/kg) daily from day CBD in neuropathic pain model: ↓ hyperalgesia to thermal (Costa et constriction 7 to 14 after the injury and mechanical stimuli; the 20 mg/kg dose normalized PGE2 al. 2007) plasma concentration and paw tissue malondialdehyde, NO Antagonists tested: capsazepine, rimonabant, SR144528 and glutathione‐related enzymes levels Vanilloid antagonist capsazepine: prevention of anti‐ hyperalgesic effect Cannabinoid receptor antagonists (rimonabant and SR144528): no effect on the withdrawal threshold 9 Mouse chronic Subcutaneous Δ9THC, CBD and Δ9‐THC:CBD co‐ Δ9‐THC: ↓ mechanical and cold allodynia; ↑ motor (Casey, constriction injury administration in doses: 0.01‐56 mg/kg incoordination, catalepsy, sedation (dose‐dependently) Atwal, (CCI) model of and Antagonists tested: AM281, AM630 (3 mg/kg) CBD: ↓ allodynia (dose‐dependently, smaller effect than Δ9‐ neuropathic pain Vaughan THC); no side effects 2017) Δ9‐THC:CBD co‐administration: ↓ allodynia (dose‐ dependently); 200‐fold increase in anti‐allodynic potency (at low doses); only high doses gave side effects (similar to Δ9‐ THC alone) AM281 (CB1 receptor antagonist): abolition of the THC effect on mechanical allodynia and cold allodynia (only parital) 10 Spinal cord injury CBD 1,5 mg/kg i.p. for 10 weeks CBD: ↓ pro‐inflammatory cytokines and chemokines; ↓ (Li et al. mouse model moderate to severe thermal sensitivity development 2018) (compared to vehicle group) 11 Peripheral sciatic Orally, in medium chain triglyceride oil, for 14 days All groups: ↓ hypersensivity in male rats (parcularly CBD: (Linher‐ nerve cuff (surgically Δ9‐THC combination); ↑ beneficial changes in myelinated Aβ Melville CBD ‐ 25 mg/60 kg per day induced neuropathic mechanoreceptive fibers et al. pain rat model) Δ9‐THC ‐ 5 mg/60 kg per day 2020) CBD: Δ9‐THC ‐ 12,5:12,5 mg/60 kg per day 12 Naive rats and 1. Intravenous (i.v.) increasing doses of CBD (0.1‐1.0 Naïve rats: acute CBD ↓ the firing rate of 5‐HT neurons in (De Spared nerve injury mg/kg) ‐ naive rats only dorsal raphe nucleus (blocked by WAY100635, 5HT1A Gregorio neuropathic pain rat antagonist and capsazepine, the TRPV1 antagonist); repeated et al. Antagonists tested: WAY 100635 (300 mg/kg), AM 251 (1 model CBD ↑ 5‐HT firing through desensitization of 5‐HT1A 2019) mg/kg), capsazepine (1 mg/kg) i.v. receptors 2. Repeated treatment with CBD (5 mg/kg/day, SNI rats: repeated CBD ↓ mechanical allodynia (blocked by subcutaneously, for 7 days ‐ naive and SNI rats capsazepine and partially by WAY100635), anxiety‐like behavior (blocked by WAY100635); normalized 5‐HT activity Antagonists tested: WAY (2 mg/kg, capsazepine (10 mg/kg) subcutaneously 13 Paclitaxel (PAC)‐ CBD 5 or 10 mg/kg i.p. CBD: prevention of cold and mechanical allodynia (Ward et induced allodynia development al. 2011) mouse model 14 PAC‐induced CBD pretreatment (2.5, 5.0 mg/kg, i.p.) CBD: PAC‐induced mechanical sensitivity prevention (effect (Ward et neuropathic pain reversed by the 5‐HT1A antagonist, but not the CB1 or CB2 al. 2014) Antagonists tested: SR141716A (CB1), SR144528 (CB2), mouse model antagonists) WAY100635 (5HT‐1A) 5 mg/kg i.p. CBD + PAC: additive to synergistic inhibition of breast cancer cell viability 15 PAC, oxaliplatin or Paclitaxel‐treated mice pretreated with CBD (0.625–20.0 CBD alone: ↓ mechanical allodynia in PAC‐ and oxaliplatin‐ (King et vincristine‐induced mg/kg i.p.), Δ9‐THC (0.625–20.0 mg/kg i.p.) or CBD + Δ9‐ treated mice al. 2017) neuropathic pain THC (0.04 + 0.04–20.0 + 20.0 mg/kg i.p.) Δ9‐THC alone: ↓ mechanical allodynia in PAC‐ and vincristine‐ mouse model Oxaliplatin/vincristine‐treated mice pretreated with CBD treated mice (1.25–10.0 mg/kg i.p.), Δ9‐THC (10.0 mg/kg i.p.) or Δ9‐ CBD + Δ9‐THC: synergistic effect of low, ineffective doses THC + CBD (0.16 mg/kg THC + 0.16 mg/kg CBD i.p.) 16 Cisplatin‐induced Experiment 1: after 8 daily administrations of cisplatin Experiment 1: ↓ neuropathy in all groups (Harris et neuropathy mouse (2,3 mg/kg): vehicle, 100 mg/kg gabapentin, 2 mg/kg Δ9‐ al. 2016) Experiment 2: no prevention of neuropathy development model THC, or 2 mg/kg CBD i.p. Experiment 2: CBD (0.0, 0.5, 1.0, and 2.0 mg/kg) or Δ9‐ THC (0.0, 0.5, 1.0, and 2.0 mg/kg) i.p. 30 min prior to cisplatin administration 17 Cisplatin‐induced CBD 2.5 to 10 mg/kg i.p. every day, starting 1.5 h before CBD: ↓ induced oxidave/nitrosave stress, inflammaon, (Pan et al. nephropathy mouse the cisplatin exposure cell death in the kidney; ↑ renal funcon 2009) model 18 Murine type I CBD: 0.1; 1; 2 mg/kg intranasal (i.n.) or 1; 10; 20 mg/kg Moderate‐high doses of intranasal and i.p.
Load more

Recommended publications
  • A1.5 Morphine A6 ATC Code: N02AA01 Oral Liquid: 2 Mg (As Hydrochloride Or Sulfate)/Ml
    A1 A2 A3 A4 A5 A1.5 Morphine A6 ATC code: N02AA01 Oral liquid: 2 mg (as hydrochloride or sulfate)/ml. Tablet: 10 mg (as sulfate). Tablet (prolonged release): 10 mg, 30 mg, 60 mg, 100 mg, 200 mg (as sulfate). Granules: (prolonged release, to mix with water): 20 mg, 30 mg, 60 mg, 100 mg, 200 mg (morphine sulfate). Injection: 10 mg (as hydrochloride or sulfate) in 1 ml ampoule. A7 Indications: moderate to severe persisting pain. 73 < Contraindications: hypersensitivity to opioid agonists or to any component of the formulation; acute respiratory depression; acute asthma; paralytic ileus; concomitant use of, or use within 14 days after ending monoamine oxidase inhibitors; raised intracranial pressure and/or head injury, if ventilation not controlled; coma; use within 24 hours before or after surgery. Precautions: impaired respiratory function; avoid rapid injection which may precipitate chest wall rigidity and difficulty with ventilation; bradycardia; asthma; hypotension; shock; obstructive or inflammatory bowel disorders; biliary tract disease; convulsive disorders; hypothyroidism; adrenocortical insufficiency; avoid abrupt withdrawal after prolonged treatment; diabetes mellitus; impaired consciousness; acute pancreatitis; myasthenia gravis; hepatic impairment; renal impairment; toxic psychosis. Skilled tasks: warn the patient or carer about the risk of undertaking tasks requiring attention or coordination, for example, riding a bike. Dosage: Starting dose for opioid-naive patients: Oral (immediate-release formulation): • infant 1–12 months – 80–200 mcg/kg every 4 hours; • child 1–2 years – 200–400 mcg/kg every 4 hours; • child 2–12 years – 200–500 mcg/kg every 4 hours; maximum oral starting dose is 5 mg. Oral (prolonged-release formulation): • child 1–12 years – initially 200–800 mcg/kg every 12 hours.
    [Show full text]
  • SAMHSA Opioid Overdose Prevention TOOLKIT
    SAMHSA Opioid Overdose Prevention TOOLKIT Opioid Use Disorder Facts Five Essential Steps for First Responders Information for Prescribers Safety Advice for Patients & Family Members Recovering From Opioid Overdose TABLE OF CONTENTS SAMHSA Opioid Overdose Prevention Toolkit Opioid Use Disorder Facts.................................................................................................................. 1 Scope of the Problem....................................................................................................................... 1 Strategies to Prevent Overdose Deaths.......................................................................................... 2 Resources for Communities............................................................................................................. 4 Five Essential Steps for First Responders ........................................................................................ 5 Step 1: Evaluate for Signs of Opioid Overdose ................................................................................ 5 Step 2: Call 911 for Help .................................................................................................................. 5 Step 3: Administer Naloxone ............................................................................................................ 6 Step 4: Support the Person’s Breathing ........................................................................................... 7 Step 5: Monitor the Person’s Response ..........................................................................................
    [Show full text]
  • Method of Rough Estimation of Median Lethal Dose (Ld50)
    b Meta olis g m & ru D T o f x o i Journal of Drug Metabolism and l c a o n l o r Saganuwan, J Drug Metab Toxicol 2015, 6:3 g u y o J Toxicology DOI: 10.4172/2157-7609.1000180 ISSN: 2157-7609 Research Article Open Access Arithmetic-Geometric-Harmonic (AGH) Method of Rough Estimation of Median Lethal Dose (Ld50) Using Up – and – Down Procedure *Saganuwan Alhaji Saganuwan Department of Veterinary Physiology, Pharmacology and Biochemistry, College Of Veterinary Medicine, University Of Agriculture, P.M.B. 2373, Makurdi, Benue State, Nigeria *Corresponding author: Saganuwan Alhaji Saganuwan, Department of Veterinary Physiology, Pharmacology and Biochemistry, College Of Veterinary Medicine, University Of Agriculture, P.M.B. 2373, Makurdi, Benue State, Nigeria, Tel: +2348027444269; E-mail: [email protected] Received date: April 6,2015; Accepted date: April 29,2015; Published date: May 6,2015 Copyright: © 2015 Saganuwan SA . This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Abstract Earlier methods adopted for the estimation of median lethal dose (LD50) used many animals (40 – 100). But for the up – and – down procedure, 5 – 15 animals can be used, the number I still consider high. So this paper seeks to adopt arithmetic, geometric and harmonic (AGH) mean for rough estimation of median lethal dose (LD50) using up – and – down procedure by using 2 – 6 animals that may likely give 1 – 3 reversals. The administrated doses should be summed up and the mean, standard deviation (STD) and standard error of mean (SEM) should be determined.
    [Show full text]
  • Medication Administration
    MEDICATION ADMINISTRATION GENERAL CONSIDERATIONS A. Before administering any medication, the EMT should know: 1. What is the medication being used? 2. Does the patient have an allergy to this medication? 3. What is the safe and effective dose? 4. What is the correct administration route? 5. What are the indications? (Why are you using is?) 6. What are the contraindications? (Why or when would you NOT use this medication?) 7. What are the expected effects? 8. What are the adverse effects / side effects? 9. Is the medication expired? B. The “Six Rights” of medication administration: 1. Right patient – is the medication indicated for this patient; no contraindications; no allergies 2. Right drug – the correct name (trade name vs. generic name); correct concentration 3. Right dose 4. Right route 5. Right time – slow IVP vs. rapid IVP 6. Right documentation C. Correct documentation of medications administered and/or IV/IO placement will include: 1. Time of medication administration; IV/IO placement 2. Route of administration 3. Size of catheter (IV/IO) 4. Site location for IV/IO and SQ, IM medication (include unsuccessful IV/IO attempt locations) 5. Dose or volume infused 6. Time of infusion as indicated (e.g., rapid IVP, infused over 10 minutes, etc.) 7. Name of EMT responsible 8. Any complications and steps made to correct 9. Patient’s response to treatment D. Use of a medication simply because it is in the protocol is not an acceptable standard of medical care. When there are questions about medication administration, consult medical control. ORAL ADMINSTRATION To administer an oral (PO) medication ensure that the patient has an intact gag reflex and place the patient in a seated or semi-seated position.
    [Show full text]
  • Test No. 408: Repeated Dose 90-Day Oral Toxicity Study in Rodents
    OECD/OCDE 408 Adopted: 25 June 2018 │ OECD GUIDELINE FOR THE TESTING OF CHEMICALS Repeated dose 90-day oral toxicity study in rodents INTRODUCTION 1. OECD Guidelines for the Testing of Chemicals are periodically reviewed in the light of scientific progress, changing regulatory needs, and animal welfare considerations. The original guideline 408 was adopted in 1981. In 1998 a revised version was adopted, to obtain additional information from the animals used in the study, based on the outcome of an OECD Consultation Meeting of Experts on Sub- chronic and Chronic Toxicity Testing held in Rome in 1995 (1). 2. This Test Guideline (TG) was updated in 2018 to add endocrine-sensitive endpoints intended to improve detection of potential endocrine activity of test chemicals and mirrors updates to TG 407 (Repeated Dose 28-Day Oral Toxicity Study in Rodents). INITIAL CONSIDERATIONS 3. In the assessment and evaluation of the toxic characteristics of a chemical, the determination of sub-chronic oral toxicity using repeated doses may be carried out after initial information on toxicity has been obtained from acute or repeated dose 28-day toxicity tests. The 90- day study provides information on the possible health hazards likely to arise from repeated exposure over a prolonged period of time covering post-weaning maturation and growth into adulthood of the test animals. The study will provide information on the major toxic effects, indicate target organs and the possibility of accumulation of test chemical, and can provide an estimate of a no-observed-adverse-effect level (NOAEL) of exposure which can be used in selecting dose levels for chronic studies and for establishing safety criteria for human exposure.
    [Show full text]
  • Young Medication Dose Calcul
    Nurse Education in Practice 13 (2013) e11ee22 Contents lists available at SciVerse ScienceDirect Nurse Education in Practice journal homepage: www.elsevier.com/nepr Safety in numbers 1: Essential numerical and scientific principles underpinning medication dose calculation Simon Young a, Keith W. Weeks a,*, B. Meriel Hutton b a Faculty of Health, Sport & Science, University of Glamorgan, UK b King’s College London, UK article info abstract Article history: Registered nurses spend up to 40% of their professional clinical practice engaged in the art and science of Accepted 17 October 2012 medication dosage calculation problem-solving (MDC-PS). In advancing this patient safety critical discipline it is our position that as a profession we must first situate MDC-PS within the context of the Keywords: wider features of the nursing numeracy, medicines management and clinical pharmacokinetic domains Medicines dosage calculations that inform its practice. This paper focuses on the essential relationship between numeracy, healthcare Healthcare numeracy numeracy, medicines management, pharmacokinetics and MDC-PS. We present a taxonomy of generic Fundamental clinical pharmacokinetics numerical competencies for the pre-registration curriculum, with examples of essential medication dosage calculation requirements mapped to each skills domain. This is followed by a review of the symbols and measurement units that represent essential components of calculation competence in healthcare and medicines management practice. Finally we outline the fundamental pharmacokinetic knowledge that explains how the body deals with medication and we illustrate through clinical corre- lations why numeric and scientific knowledge and skills must be mastered to ensure safe dosage calculation and medicines management practice. The findings inform nurse education practice via advancing our understanding of a number of issues, including a unified taxonomy of generic numerical competencies mapped to the 42 revised UK Nursing and Midwifery Council (NMC) Essential Skills Clusters (NMC, 2010a; NMC, 2010b).
    [Show full text]
  • Psychoactive Prescription Drug Use Disorders, Misuse and Abuse Pharmacoepidemiological Aspects
    Psychoactive prescription drug use disorders, misuse and abuse Pharmacoepidemiological aspects Micaela Tjäderborn Division of Drug Research Institution of Medical and Health Sciences Linköping University Linköping, Sweden 2016 Psychoactive prescription drug use disorders, misuse and abuse © Micaela Tjäderborn 2016 [email protected] ISBN: 978-91-7685-770-0 ISSN: 0345-0082 Printed in Linköping, Sweden 2016 Liu-Tryck AB ii All the passionate work I put into this thesis is dedicated to my parents, who always emphasized the importance of knowledge and of caring for the less fortunate. iii iv Psychoactive prescription drug use disorders, misuse and abuse Pharmacoepidemiological aspects Micaela Tjäderborn Division of Drug Research Institution of Medical and Health Sciences Linköping University, Linköping, Sweden Background: There is a widespread and increasing use of psychoactive prescription drugs, such as opioid analgesics, anxiolytics, hypnotics and anti-epileptics, but their use is associated with a risk of drug use disorder, misuse and abuse. Today, these are globally recognised and emerging public health concerns. Aim: The aim of this thesis is to estimate the occurrence and prevalence of psychoactive prescription drug use disorders, misuse and abuse, and to investigate the association with some potential risk factors. Methods: A study using register data from forensic cause of death investigations analysed and described cases of fatal unintentional intoxications with tramadol (Study I). Based on register data on spontaneously reported adverse drug reactions (ADRs) reported cases of tramadol dependence were scrutinized and summarised (Study II). In a study in suspected drug-impaired drivers with a toxicology analysis confirming intake of tramadol, diazepam, flunitrazepam, zolpidem and zopiclone, the prevalence of non-prescribed use was assessed and associated factors were investigated (Study III).
    [Show full text]
  • 1. Administering Vaccines: Dose, Route, Site, and Needle Size
    Administering Vaccines: Dose, Route, Site, and Needle Size Vaccine Dose Route Injection Site and Needle Size Pfizer-BioNTech Subcutaneous (Subcut) injection ≥12 yrs: 0.3 mL COVID-19 IM . Use a 23–25 gauge needle. Choose the injection site that is appropriate to Moderna; Janssen the person’s age and body mass. ≥18 yrs: 0.5 mL Needle Diphtheria, Tetanus, Pertussis age injection site 0.5 mL. IM .. length (DTaP, DT, Tdap, Td) Fatty tissue over anterolateral Infants (1–12 mos) ⅝" Haemophilus influenzae type b (Hib) 0.5 mL IM thigh muscle ≤18 yrs: 0.5 mL Fatty tissue over anterolateral Hepatitis A (HepA) IM Children 12 mos or older, ⅝" thigh muscle or fatty tissue ≥19 yrs: 1.0 mL adolescents, and adults over triceps Engerix-B; Recombivax HB Hepatitis B (HepB) ≤19 yrs: 0.5 mL Intramuscular (IM) injection Persons 11–15 yrs may be given Recombivax HB (Merck) ≥20 yrs: 1.0 mL IM Use a 22–25 gauge needle. Choose the injection site and needle length that 1.0 mL adult formulation on a 2-dose schedule. Heplisav-B is appropriate to the person’s age and body mass. ≥18 yrs: 0.5 mL needle Human papillomavirus (HPV) 0.5 mL IM age length injection site 0.2 mL (0.1 mL in Intranasal 1 Influenza, live attenuated (LAIV) Newborns (1st 28 days) ⅝" Anterolateral thigh muscle each nostril) spray Infants (1–12 mos) 1" Anterolateral thigh muscle Afluria: 0.25 mL 1–1¼" Anterolateral thigh muscle2 Influenza, inactivated (IIV); for ages Fluzone: 0.25 or 0.5 mL Toddlers (1–2 years) IM 1 6–35 months ⅝–1" Deltoid muscle of arm FluLaval; Fluarix: 0.5 mL Children ⅝–1"1 Deltoid
    [Show full text]
  • RADIOPHARMACEUTICALS Final Text for Addition to the International Pharmacopoeia (November 2008)
    Document QAS/08.262/FINAL November 2008 RADIOPHARMACEUTICALS Final text for addition to The International Pharmacopoeia (November 2008) This text was adopted at the Forty-third WHO Expert Committee on Specifications for Pharmaceutical Preparations in October 2008 for addition to the 4 th edition of The International Pharmacopoeia . Contents Introduction Monographs General monograph Specific monographs Methods of Analysis Supplementary Information Introduction Radiopharmaceuticals are unique medicinal formulations containing radioisotopes which are used in major clinical areas for diagnosis and/or therapy. The facilities and procedures for the production, use, and storage of radiopharmaceuticals are subject to licensing by national and/or regional authorities. This licensing includes compliance both with regulations governing pharmaceutical preparations and with those governing radioactive materials. Additional regulations may apply for issues such as transportation or dispensing of radiopharmaceuticals. Each producer or user must be thoroughly cognizant of the national requirements pertaining to the articles concerned. Regulations concerning pharmaceutical preparations include the application of current Good Manufacturing Practices (GMP). Guidelines are available in Quality assurance of pharmaceuticals, Volume 2: Good manufacturing Document QAS/08.262/FINAL page 2 practices and inspection (WHO, Geneva, 2004); for the current WHO recommendations consult the WHO Medicines web site (http://www.who.int/medicines). Regulations governing radioactive materials include those on safe handling and production of radioisotopes. See International Basic Safety Standards for Protection against Ionizing Radiation and for the Safety of Radiation Sources (IAEA, Vienna, 2003, CD-ROM Edition) Safety Series No. 115/CD and Radiological Protection for Medical Exposure to Ionizing Radiation Safety Guide (IAEA, Vienna, 2002) Safety Standard Series No.
    [Show full text]
  • E 4: Dose Response Information to Support Drug Registration
    European Medicines Agency November 1994 CPMP/ICH/378/95 ICH Topic E 4 Dose Response Information to Support Drug Registration Step 5 NOTE FOR GUIDANCE ON DOSE RESPONSE INFORMATION TO SUPPORT DRUG REGISTRATION (CPMP/ICH/378/95) APPROVAL BY CPMP May 1994 DATE FOR COMING INTO OPERATION November 1994 7 Westferry Circus, Canary Wharf, London, E14 4HB, UK Tel. (44-20) 74 18 85 75 Fax (44-20) 75 23 70 40 E-mail: [email protected] http://www.emea.eu.int EMEA 2006 Reproduction and/or distribution of this document is authorised for non commercial purposes only provided the EMEA is acknowledged DOSE-RESPONSE INFORMATION TO SUPPORT DRUG REGISTRATION ICH Harmonised Tripartite Guideline 1. INTRODUCTION Purpose of Dose-Response Information Knowledge of the relationships among dose, drug-concentration in blood, and clinical response (effectiveness and undesirable effects) is important for the safe and effective use of drugs in individual patients. This information can help identify an appropriate starting dose, the best way to adjust dosage to the needs of a particular patient, and a dose beyond which increases would be unlikely to provide added benefit or would produce unacceptable side effects. Dose-concentration, concentration- and/or dose-response information is used to prepare dosage and administration instructions in product labeling. In addition, knowledge of dose-response may provide an economical approach to global drug development, by enabling multiple regulatory agencies to make approval decisions from a common database. Historically, drugs have often been initially marketed at what were later recognized as excessive doses (i.e., doses well onto the plateau of the dose-response curve for the desired effect), sometimes with adverse consequences (e.g.
    [Show full text]
  • Guidance for Industry
    Guidance for Industry Dosage and Administration Section of Labeling for Human Prescription Drug and Biological Products — Content and Format U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER) Center for Biologics Evaluation and Research (CBER) March 2010 Labeling Guidance for Industry Dosage and Administration Section of Labeling for Human Prescription Drug and Biological Products — Content and Format Additional copies are available from: Office of Communications, Division of Drug Information Center for Drug Evaluation and Research Food and Drug Administration 5600 Fishers Lane Rockville, MD 20857 (Tel) 301-827-4573 http://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/default.htm or Office of Communication, Outreach and Development, HFM-40 Center for Biologics Evaluation and Research Food and Drug Administration 1401 Rockville Pike Rockville, MD 20852-1448 (Tel) 800-835-4709 or 301-827-1800 http://www.fda.gov/BiologicsBloodVaccines/GuidanceComplianceRegulatoryInformation/Guidances/default.htm U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER) Center for Biologics Evaluation and Research (CBER) March 2010 Labeling Contains Nonbinding Recommendations 1 2 TABLE OF CONTENTS 3 4 I. INTRODUCTION............................................................................................................. 1 5 II. DOSAGE AND ADMINISTRATION SECTION — CONTENT...............................
    [Show full text]
  • Guidance for Industry: M3(R2) Nonclinical Safety Studies for the Conduct of Human Clinical Trials
    Guidance for Industry M3(R2) Nonclinical Safety Studies for the Conduct of Human Clinical Trials and Marketing Authorization for Pharmaceuticals U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER) Center for Biologics Evaluation and Research (CBER) January 2010 ICH Revision 1 Guidance for Industry M3(R2) Nonclinical Safety Studies for the Conduct of Human Clinical Trials and Marketing Authorization for Pharmaceuticals Additional copies are available from: Office of Communications Division of Drug Information Center for Drug Evaluation and Research Food and Drug Administration 10903 New Hampshire Ave. Bldg. 51, Room 2201 Silver Spring, MD 20993-0002 (Tel) 301-796-3400 http://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/default.htm and/or Office of Communication, Outreach and Development, HFM-40 Center for Biologics Evaluation and Research Food and Drug Administration 1401 Rockville Pike, Rockville, MD 20852-1448 (Tel) 800-835-4709 or 301-827-1800 http://www.fda.gov/BiologicsBloodVaccines/GuidanceComplianceRegulatoryInformation/Guidances/default.htm. U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER) Center for Drug Evaluation and Research (CBER) January 2010 ICH Revision 1 Contains Nonbinding Recommendations TABLE OF CONTENTS List of Abbreviations I. INTRODUCTION (1)....................................................................................................... 1 A. Objectives
    [Show full text]